A study using the NIH All of Us Research Program found that essentially all participants carried at least one pharmacogenomic variant affecting how their body processes medications, and about a quarter had been prescribed a drug known to be impacted by the variant they carry. Researchers argue this supports broader PGx testing and the use of EHR alerts to guide prescribing. The work points to the scale of genotype-guided dosing opportunities that already exist in FDA labeling and CPIC guidance for hundreds of medications. For clinicians and health systems, the key operational question becomes how to integrate testing logistics, interpretation, and alerting into routine workflows without generating alert fatigue.